IP Verse

Semaglutide In Cardiovascular Conditions

PatentPatent Analysis

EP3448416

NOVO NORDISK
Application Number
EP17721109A
Filing Date
Apr 28, 2017
Status
Granted And Under Opposition
Jul 8, 2022
Grant Date
Aug 10, 2022
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3300721B2
EP2729202B2
EP3897582B1

Bibliography

The patent EP3448416B1 was granted to Novo Nordisk on Aug 10, 2022 following the initial filing on Apr 28, 2017 under the application number EP17721109A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

APPLEYARD LEESMay 10, 2023ADMISSIBLE
DR SCHONMay 10, 2023ADMISSIBLE
GENERICS UKMay 10, 2023ADMISSIBLE
ADALVOMay 9, 2023ADMISSIBLE
ELKINGTON AND FIFEMay 9, 2023ADMISSIBLE
SANDOZMay 9, 2023ADMISSIBLE
TEVA PHARMACEUTICALSMay 9, 2023ADMISSIBLE
STADA ARZNEIMITTELMay 5, 2023ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents